Inventor · disambiguated record
Kevin Peters
Also filed as: PETERS KEVIN · PETERS KEVIN G · PETERS KEVIN GENE
36 granted patents·44 pending applications·573 citations·filing 2002–2024
98Inventor score
Files withAERPIO THERAPEUTICS INC36AERPIO PHARMACEUTICALS INC15EYEPOINT PHARMACEUTICALS INC14PROCTER & GAMBLE7AERPIO THERAPEUTICS LLC2
Top patents by PatentIndex Score
80 records- 0198US9949956B2Compounds, compositions, and methods for preventing metastasis of cancer cellsAERPIO THERAPEUTICS INC·Filed 2015·Granted Apr 24, 2018·21 cites·18 claims
- 0298US9174950B2Compounds, compositions, and methods for preventing metastasis of cancer cellsAERPIO THERAPEUTICS INC·Filed 2014·Granted Nov 3, 2015·32 cites·20 claims
- 0397US10220048B2Compositions and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2016·Granted Mar 5, 2019·19 cites·13 claims
- 0497US9440963B2Compositions, formulations and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2014·Granted Sep 13, 2016·35 cites·60 claims
- 0597US9096555B2Methods for treating vascular leak syndromeAERPIO THERAPEUTICS INC·Filed 2012·Granted Aug 4, 2015·32 cites·2 claims
- 0697US8883832B2Compounds, compositions, and methods for preventing metastasis of cancer cellsAERPIO THERAPEUTICS INC·Filed 2013·Granted Nov 11, 2014·38 cites·52 claims
- 0797US8569348B2Compounds, compositions, and methods for preventing metastasis of cancer cellsSHALWITZ ROBERT·Filed 2010·Granted Oct 29, 2013·37 cites·15 claims
- 0896US11180551B2Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)EYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Nov 23, 2021·6 cites·34 claims
- 0996US8999325B2Treatment of ocular diseaseAERPIO THERAPEUTICS INC·Filed 2012·Granted Apr 7, 2015·36 cites·18 claims
- 1095US11136389B2Humanized monoclonal antibodies that target VE-PTP (HPTP-β)AERPIO PHARMACEUTICALS INC·Filed 2020·Granted Oct 5, 2021·5 cites·33 claims
- 1195US10329357B2Treatment of ocular diseaseAERPIO THERAPEUTICS INC·Filed 2017·Granted Jun 25, 2019·16 cites·11 claims
- 1295US10253094B2Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditionsAERPIO THERAPEUTICS INC·Filed 2017·Granted Apr 9, 2019·13 cites·45 claims
- 1395US10150811B2Methods for treating vascular leak syndrome and cancerAERPIO THERAPEUTICS INC·Filed 2017·Granted Dec 11, 2018·15 cites·14 claims
- 1495US9926367B2Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereofAERPIO THERAPEUTICS INC·Filed 2017·Granted Mar 27, 2018·23 cites·11 claims
- 1595US7632862B2Pharmaceutical compositions that modulate HPTPbeta activityPROCTER & GAMBLE·Filed 2007·Granted Dec 15, 2009·35 cites·4 claims
- 1695US7226755B1HPTPbeta as a target in treatment of angiogenesis mediated disordersPROCTER & GAMBLE·Filed 2003·Granted Jun 5, 2007·68 cites·18 claims
- 1794US11253502B2Tie-2 activators targeting the Schlemm's canalEYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Feb 22, 2022·3 cites·39 claims
- 1894US10604569B2Humanized monoclonal antibodies that target protein tyrosine phosphatase-beta (HPTP-β/VE-PTP)AERPIO THERAPEUTICS LLC·Filed 2018·Granted Mar 31, 2020·12 cites·36 claims
- 1994US10597452B2Methods of treating ocular conditions by administering humanized monoclonal antibodies that target VE-PTP (HPTP-beta)AERPIO THERAPEUTICS LLC·Filed 2018·Granted Mar 24, 2020·11 cites·46 claims
- 2094US7973142B2Antibodies that bind human protein tyrosine phosphatase beta (HPTPβ)Warner Chilcott Company·Filed 2007·Granted Jul 5, 2011·46 cites·16 claims
- 2193US11873334B2Method of treating ocular conditions by administering an antibody that activates Tie2 and binds VEGFEYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Jan 16, 2024·2 cites·19 claims
- 2292US12145986B2Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta)EYEPOINT PHARMACEUTICALS INC·Filed 2022·Granted Nov 19, 2024·1 cites·20 claims
- 2392US11666558B2Methods of treating intraocular pressure with activators of Tie-2EYEPOINT PHARMACEUTICALS INC·Filed 2021·Granted Jun 6, 2023·2 cites·10 claims
- 2492US10894824B2Multispecific antibodies that target HPTP-β (VE-PTP) and VEGFAERPIO PHARMACEUTICALS INC·Filed 2019·Granted Jan 19, 2021·6 cites·32 claims
- 2592US8524235B2Method for treating coronary artery disease using antibody binding human protein tyrosine phosphatase beta(HPTPbeta)ROTELLO ROCCO JAMIE·Filed 2011·Granted Sep 3, 2013·35 cites·15 claims
- 2690US11814425B2Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereofEYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Nov 14, 2023·2 cites·10 claims
- 2788US10815300B2Methods for treating vascular leak syndrome and cancerAERPIO PHARMACEUTICALS INC·Filed 2018·Granted Oct 27, 2020·5 cites·11 claims
- 2888US9994560B2HPTP-β inhibitorsAERPIO THERAPEUTICS INC·Filed 2015·Granted Jun 12, 2018·8 cites·36 claims
- 2986US12043664B2Methods for treating vascular leak syndrome and cancerEYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Jul 23, 2024·1 cites·13 claims
- 3086US10952992B2Methods of treating intraocular pressure with activators of Tie-2AERPIO PHARMACEUTICALS INC·Filed 2016·Granted Mar 23, 2021·4 cites·32 claims
- 3184US11413242B2Formulations of Tie-2 activators and methods of use thereofEYEPOINT PHARMACEUTICALS INC·Filed 2020·Granted Aug 16, 2022·1 cites·26 claims
- 3283US12398204B2Method of treating an ocular condition by administering multispecific antibodies that activates TIE2 and binds a receptor tyrosine kinase agonistEYEPOINT PHARMACEUTICALS INC·Filed 2023·Granted Aug 26, 2025·0 cites·19 claims
- 3382US12152023B2Compositions, formulations and methods for treating ocular diseasesEYEPOINT PHARMACEUTICALS INC·Filed 2022·Granted Nov 26, 2024·0 cites·18 claims
- 3481US10858354B2HPTP-Beta inhibitorsAERPIO PHARMACEUTICALS INC·Filed 2018·Granted Dec 8, 2020·3 cites·3 claims
- 3579US12171751B2Methods of treating intraocular pressure with activators of Tie-2EYEPOINT PHARMACEUTICALS INC·Filed 2023·Granted Dec 24, 2024·0 cites·20 claims
- 3678US2025082613A1Tie-2 activators targeting the schlemm's canalEYEPOINT PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3778US2020207730A1Methods for treating vascular leak syndromeAERPIO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3874US12064420B2Tie-2 activators targeting the Schlemm's canalEYEPOINT PHARMACEUTICALS INC·Filed 2022·Granted Aug 20, 2024·0 cites·16 claims
- 3973US2020361926A1Compositions, formulations and methods for treating ocular diseasesAERPIO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4072US2018237429A1Compositions, formulations and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4172US2018237430A1Compositions, formulations and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4272US2018237431A1Compositions, formulations and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4371US2020277267A1Methods for treating vascular leak syndromeAERPIO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4470US2015050277A1Compositions and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 4569US2020108080A1Compositions and methods for treating ocular diseasesAERPIO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4669US2020009115A1Compositions and methods for treating ocular edema, neovascularization and related diseasesAERPIO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4769US2023139250A1Formulations of tie-2 activators and methods of use thereofEYEPOINT PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4869US2018022741A1Compositions, formulations and methods for treating ocular diseasesAERPIO THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4969US2022016086A1Compositions and methods for treating ocular edema, neovascularization and related diseasesAERPIO PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 5068US2020231703A1Treatment of ocular diseaseAERPIO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 80 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →